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1. Introduction
Since the late 1920s, the importance of the physiological role of adenosine triphosphate (ATP)
and its metabolites, mainly adenosine, has been clear. In 1970, strong evidence now suggests
ATP as a neurotransmitter in nonadrenergic, noncholinergic (NANC) nerves supplying the
gut. Initially, the hypothesis of purinergic transmission encountered some resistance, however,
this concept is now widely accepted and purines are considered powerful extracellular
messengers in peripheral and central nervous system and to non-neuronal cells, including
immune, and inflammatory cells. Implicit in the purinergic hypothesis was the presence of
purinoceptors. The first evidence for the existence of adenosine receptors, responsible for the
physiological effects of adenosine, was only published in the beginning of the 1970s. Through‐
out the 1990s and 2000s adenosine receptors were cloned, and the mechanisms of signal
transduction mediated by these receptors were described. Currently, it is well known that
adenosine activates four G protein-coupled receptors named A1, A2A, A2B and A3. The A1 and
A3 receptors preferentially interact with members of the Gi/o family of G proteins, lowering the
intracellular levels of cyclic adenosine monophosphate (cAMP), whereas the A2A and A2B
receptors interact with members of the Gs family of G proteins, elevating of intracellular cAMP.
Throughout the 1980s and 1990s, several studies demonstrated that ATP metabolites, espe‐
cially adenosine, are important signaling molecules, and adenosine receptors are important
molecular targets in inflammation and immunity. During inflammation, the generation of the
appropriate immune response can itself cause considerable damage and thus requires effective
regulation. It has been suggested that this regulation of the immune system requires the
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sensing of specific signals called “danger signals”. Thus, in the context of purinergic signaling,
it has been proposed that the regulation of the immune system requires at least two ‘danger’
signals, the first (ATP) indicating the presence of danger from pathogens or other injurious
events and leading to the activation of immune cells and defensive effector function and the
second (adenosine) indicating the danger from overactive immune cells and triggering the
downregulation of the proinflammatory activities of the immune system. These discoveries
increased the interest in the purinergic signaling pathways, and there was an increase in
publications studying the effects of adenosine and inosine in inflammation and immunity
(Figure 1 A and B).
Substantial evidence demonstrates that adenosine receptors are expressed in most inflamma‐
tory cells and may therefore modulate different steps involved in inflammatory and immune
responses. Moreover, several recent studies have indicated that inosine, a metabolite of
adenosine, once believed to be an inert metabolite, can exert many immunomodulatory actions
through adenosine receptors, mainly the A2 and A3 receptors. In this regard, adenosine
receptors have become potential therapeutic targets for the treatment of several pathologies
in which inflammatory modulation is a key component. In this regard, adenosine and inosine
can be considered molecules with valuable therapeutic potential, performing the desired effect
with minimal side effects, such as those present in therapy with adenosine (Adenocard®) for
the treatment of paroxysmal supraventricular tachycardia (facial flushing, chest pressure,
hyperventilation, dizziness, numbness and tingling). Moreover, no studies clearly demon‐
strate the side effects of inosine. However, it is important to warn that the purines can play
deleterious effects not observed clinically, depending on the target tissue and the receptor that
is activated according to figure 3.
Thus, this chapter was designed to highlight the importance of ATP metabolites, especially
adenosine and inosine, and their modulatory effect on inflammation through the activation of
adenosine receptors. In addition, we aimed to provide updated information about the
pharmacology of adenosine receptors, especially about its proinflammatory versus anti-
inflammatory effects. Furthermore, we are able to clarify the overall effect of adenosine and
inosine in different inflammatory diseases. Finally, we intend to present a short overview
concerning the advances in drug development targeting adenosine receptors.
2. The ATP metabolic pathways
Carbohydrates, lipids and proteins, also called "metabolic fuels" are constantly being oxidized
to provide energy. Glucose is generally the primary energy source for cellular metabolism. It
is catabolized by the following three main processes: glycolysis, the tricarboxylic acid (TCA or
Krebs) cycle and oxidative phosphorylation, which lead to the production of ATP, the final
energy-rich product that is used in many different active processes in an organism. Macro‐
molecule synthesis, muscle contraction, active transport of ions and thermogenesis are some
of the key processes that require energy. Since the mid-1920s, when ATP was discovered as a
substrate used in muscle contraction, knowledge about this high-energy molecule has
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constantly been expanded. The literature has shown that many aspects of cellular metabolism
are directly linked to the production and consumption of ATP and has also emphasized its
importance in purinergic signaling mechanisms. In this context, taking into account the
importance of ATP in the maintenance of homeostasis and the evidence indicating the role of
its metabolites in the control of immunity and inflammation, understanding ATP metabolism
in the body has become more imperative [1].
2.1. The degradation of ATP and formation of ADP, adenosine and inosine
In situations of high energy demand such as inflammation and hypoxia, ATP may be converted
into adenosine monophosphate (AMP) in the intracellular environment through a reaction
dependent on ATPase and adenylate kinase. AMP can be converted into adenosine by the
intracellular enzyme 5-nucleotidase and thereafter can be transported to the extracellular
environment via bidirectional nucleoside transporters. ATP in the extracellular environment
can activate P2 –type receptors in the surroundings or generate adenosine via ecto-5-nucleo‐
tidase (NT5'E), the primary enzyme responsible for ATP metabolism under physiological
conditions [2]. In the extracellular space, ATP and ADP are converted to AMP through the
ectonucleoside triphosphate diphosphohydrolase-1 (CD39). The second step for extracellular
adenosine formation is the ecto-5'-nucleotidase (CD73) conversion of extracellular AMP into
adenosine. During inflammation and hypoxia, an increase in the activity and expression of
adenosine deaminase and in its binding partner, CD26, has also been demonstrated [3]. This
increase promotes adenosine conversion into inosine within seconds, terminates adenosine
signaling and can thus initiate inosine signaling. Inosine can be converted into hypoxanthines
and uric acid (UA) by purine nucleoside phosphorylase (PNP) and xanthine oxidase (XO),
respectively [4, 5]. Current studies using mice lacking the CD39 and CD73 genes have revealed
the importance of these enzymes in contributing to extracellular adenosine generation in
different organs and situations [5]. In agreement with those studies, certain CD39 polymor‐
phisms increase ATP and ADP, lowering extracellular adenosine levels, which can lead to
increased susceptibility to inflammatory pathological conditions such as inflammatory bowel
disease (IBD) and multiple sclerosis (MS) [6, 7]. Furthermore, the loss-of-function mutation of
CD73 in humans is suggested to be the basis for the development of peripheral arterial
calcifications, indicating that adenosine generation can be vasoprotective [8, 9]. Currently, it
is known that after adenosine is released from cells or generated in extracellular space, it
diffuses into the surroundings, where it binds to adenosine receptors (A1, A2A, A2B and A3) on
adjacent cells. Finally, after adenosine generation and receptor activation, adenosine diffuses
away from the receptor and is rapidly transported into the intracellular space mainly through
equilibrate nucleoside transporters (ENT-1 and ENT-2) [5, 10, 11].
3. ATP metabolites as danger signals: the role of adenosine and inosine
During inflammation, infection or hypoxia, the generation of the appropriate immune
response can itself cause considerable damage and thus requires effective regulation [12]. It
has been suggested that this regulation of the immune system requires the sensing of specific
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signals called “danger signals” [13-15]. Although the immune response can be activated by
recognizing the signatures of foreign pathogens, collectively called pathogen-associated
molecular patterns (PAMPs), it is also able to respond to endogenous host molecules to trigger
inflammatory responses. Most of these are produced as a result of cell death or injury or by
tumor cells; they include degradation products of the extracellular matrix (ECM), heat-shock
proteins and high-mobility group box 1 (HMGB1) proteins, UA crystals, amyloid-β and
oxidized LDL (Ox-LDL), which act as stimulators for pattern recognition receptors (PRRs) and
have been referred to as danger-associated molecular patterns (DAMPs) [15, 16].
Extracellular ATP and UA are well-characterized dangers signals, likely released from cells as
a consequence of cell damage or nonapoptotic cell death. The exposure of local cells to elevated
extracellular ATP and monosodium urate crystals has been described as proinflammatory
because it activates P2X7 receptors, NALP3 (a member of NOD-like receptors, also called
cryopyrin) and caspase-1 [17-19]. This activation leads to the processing and release of
interleukin 1β (IL-1β) and results in inflammation [14, 20]. Furthermore, the elevation of
extracellular ATP has been demonstrated to guide circulating neutrophils to the inflammatory
microenvironment and can function as a “find-me signal” to attract inflammatory cells
(particularly phagocytes) and direct the inflammatory response [12, 21].
Recent studies have shown that in situations of inflammation, trauma or hypoxia when
extracellular ATP concentrations are elevated, there is an increased expression of ectonucleo‐
tidases that rapidly convert ATP/ ADP into adenosine, terminating the proinflammatory
effects of ATP [12]. Thus, in the context of purinergic signaling, it has been proposed that the
regulation of the immune system requires at least two ‘danger’ signals, the first (ATP)
indicating the presence of danger from pathogens or other injurious events and leading to the
activation of immune cells and defensive effector function and the second (adenosine)
indicating the danger from overactive immune cells and triggering the downregulation of the
proinflammatory activities of the immune system [13, 22].
The effects of adenosine in different tissues may depend upon the repertoire of adenosine
receptors present on the cell surfaces [22]. In this context, the A2A and A2B receptors have been
described as the receptors most involved in the control of immunity and inflammation [13, 22,
23]. By binding to A2A and A2B receptors, adenosine triggers cAMP elevation in T cells, which
results in the activation of CREB/ATF (cAMP-responsive element (CRE)-binding protein/
activating transcription factor), an immunosuppressive mechanism [12, 23, 24]. This activation
has been shown to trigger Treg cell activation, the production of anti-inflammatory cytokines
such as TGF-β and IL-10 and inhibit the functional response of TCR- activated T effector cells,
reducing the secretion of IL-2 and IFN-γ [24]. Moreover, similar to adenosine, the metabolite
inosine is also known to exert wide raging anti-inflammatory effects, which include inhibition
of proinflammatory cytokines, chemokine production and protection from septic shock, colitis
and acute lung injury [25-27]. Some studies have shown that inosine can stimulate adenosine
A2A receptors and is protective in models of concanavalin A-induced liver damage, endotoxin-
induced sepsis [28, 29] and TNBS-induced colitis [30]. In this context, although there is no
description of inosine as a danger signal in the current literature, some studies have described
inosine as tissue protective. Taking into account that it can activate the same sensors (receptors)
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as adenosine, we speculate that inosine might be an additional danger signal that could work
with adenosine to dampen inflammation.
In summary, the immunosuppressive effects of adenosine have been broadly described in the
literature as a “retaliatory metabolite” [31] or an “engineer” of inflammation [22], indicating
that adenosine can manipulate the intensity and the time course of inflammatory process in
vivo and suggesting biochemical control of immunity. These events appear to be biologically
coordinated and may constitute a homeostatic mechanism of tissue integrity. Therefore, the
failure of this protective mechanism may contribute to beginning and perpetuating chronic
inflammation response.
Figure 1. The number of publications regarding the investigation of adenosine and inosine effects in inflammation
and immunity since the 1960s.
4. Adenosine receptors and inflammation: proinflammatory versus anti-
inflammatory effects
4.1. A1 adenosine receptors
The adenosine A1 receptor is coupled to the Gi/0 family of G proteins, lowering the intracellular
levels of cAMP [32, 33]. Activation of A1 receptors leads to increased intracellular Ca+2 levels
due to the stimulation of phospholipase C, which in turn promotes the cleavage of phospha‐
tidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and inositol 1,4,5-trisphos‐
phate (IP3) (Figure 2). Moreover, the enhancement of intracellular calcium can activate certain
enzymes, such as protein kinase C (PKC), phospholipase D (PLD), phospholipase A2 (PLA2)
and others [10, 33].
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The recently reported crystal structure confirms that adenosine receptors display the typical
topology of GPCRs, a common central core domain consisting of seven transmembrane (TM)
helices numbered from 1 to 7 that are composed of 20-27 amino acids and that are largely α-
helical. The TM domains are also slightly bent and linked by three intracellular (IL-1, IL-2 and
IL-3) and three extracellular (EL1, EL2, and EL3) loops [34]. The A1 receptor amino acid
sequence varies from 324 to 328 residues [35]. In 1992, Ijzerman and colleagues highlighted
the role of two histidine residues in ligand binding, one located in TM6 and one in TM7 [36].
This result was in agreement with the first mutagenesis data on adenosine receptors, published
in the same year, performed on bovine A1 receptors, which demonstrated that residues His251
(6.52) and His278 (7.43) were important for ligand binding. The same study also revealed that
the mutation of histidine residues to leucine led to a decrease in ligand affinity, especially
His278 [37]. In 1994, two mutagenesis studies suggested a role of residue 270 (7.35, isoleucine
or methionine in the bovine/canine receptor) in the binding of N6-adenine substituted
compounds (A1 receptor agonists) and the importance of residue 277 (7.42, threonine in
human/bovine receptor) in the recognition and interaction of the adenosine ribose moiety [38,
39]. It has also been demonstrated that the Pro25Leu (1.48) mutation and substitution of Leu88
(3.33), Thr91 (3.36), and Gln92 (3.37) by alanine reduces the affinity for N6-unsubstituted
adenosine derivatives [39]. In the same study, it was also demonstrated that the Gly14Thr (1.37)
mutation increases the receptor’s affinity for agonists, suggesting the constitutively active form
of this mutant receptor [40]. Finally, analysis of the Thr277Ala (7.42) mutation by an allosteric
enhancer suggested an allosteric role for this residue [41].
There is no consensus regarding the effects of A1 receptors in the inflammatory response; some
studies suggest proinflammatory effects, while others suggest anti-inflammatory effects. The
A1 receptors are expressed in leukocytes. At submicromolar adenosine concentrations, the
activation of these receptors in human neutrophils produces a proinflammatory response by
promoting chemotaxis and adherence to the endothelium [42, 43]. In lymphocytes, A1 receptor
antagonism contributes to adenosine’s anti-inflammatory effects by reducing the expression
of intracellular adhesion molecule-1 (ICAM-1), production of IL-12 and IFN-γ and lymphocyte
proliferation [44]. In addition to these data, various studies with selective agonists and
antagonists demonstrated the proinflammatory effects of A1 receptors in different inflamma‐
tory models, some of which are summarized here. During acute pancreatitis induced with
cerulein or taurocholate in rats, the selective A1 receptors agonist CCPA (2-chloro-N6-
cyclopentyladenosine) produced an increase in leukocyte infiltration and interstitial edema in
pancreatic tissue, which was attenuated by FK-838 (6-oxo-3-(2-phenylpyrazolo[1,5-α]pyri‐
din-3-yl)-1(6H)-pyridazinebutanoic acid), a selective A1 receptor antagonist [45]. A1 receptor
antagonism was also protective in the lungs; treatment with DPCPX (8-cyclopentyl-1,3-
dipropylxanthine), an A1 receptor antagonist, prevented endothelial damage, neutrophil
migration and alveolar injury in a model of ischemia reperfusion in the lungs [46]. In another
interesting study, the A1 receptor antagonist DPSPX (1,3-dipropyl-8-p-sulfophenylxanthine)
decreased the area of cardiac necrosis and improved ventricular function in a canine model of
myocardial ischemia reperfusion, most likely due to inhibition of neutrophil chemoattraction
[43]. Pretreatment with KW3902, a selective A1 receptor antagonist, preserved hepatic archi‐
tecture, decreasing the infiltration of neutrophils into hepatic tissue in a hepatic ischemia
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reperfusion injury model in dogs [47]. Collectively, these findings demonstrate that the A1
receptor is an important target in inflammation and that antagonists may be efficacious as anti-
inflammatory drugs.
In opposition to such data, studies using pharmacological (selective A1 receptor agonist or
antagonists) and genetic tools (knockout animals) have shown that activation of the A1 receptor
can promote anti-inflammatory effects. CCPA, an A1 receptor agonist, presented a protective
effect in a mouse model of renal ischemia reperfusion, an effect reverted by DPCPX, a selective
A1 receptor [48]. Studies performed with knockout mice confirmed the renal protective effects
of the A1 receptor [49] and also revealed the protective effects of this receptor in other tissues
and inflammatory conditions because the absence of the A1 receptor promotes proinflamma‐
tory effects in the lungs, enhancing leukocyte migration and levels of cytokines, including IL-4
and IL-13 [50]. In the central nervous system (CNS), A1 receptor knockout animals exhibited
severe demyelination and axonal injury, involving the activation of macrophages and micro‐
glial cells [51]. In sepsis induced in mice, the A1 receptor knockout animals had a higher degree
of renal dysfunction induced by higher release of pro-inflammatory cytokines [52]. A previous
study described the mechanism by which activation of A1 receptor leads to anti-inflammatory
effects, which involves phosphorylation of ERK, MAPK and Akt (Figure 2), all of which are
involved in the upregulation of cytoprotective genes and also increase the phosphorylation of
heat shock protein (HSP) 27, a molecular chaperone that prevents the denaturation and
aggregation of cellular proteins, a cytoprotective effect [53]. In summary, the lack of consensus
regarding the existence of the proinflammatory and anti-inflammatory effects of the adenosine
A1 receptor could be explained assuming that the A1 receptor can activate intracellular
signaling pathways that result in tissue injury or protection, through proinflammatory or anti-
inflammatory effects, respectively, because the activated pathways depend on the following:
• the species/tissue/organ and the stage/progression of injury;
• Predominant inflammatory cell type as a function of species;
• Intracellular signaling and desensitization mechanisms as a function of species or cell/tissue/
organ.
4.2. A2A adenosine receptors
Most A2A receptors are coupled to the Gs protein family. A subset, preferentially located in the
striatum, is coupled to the Golf protein family. It is well established that the biological effects
triggered by A2A receptors are due to enhancement of cAMP production followed by adenylate
cyclase activation. The increase of the cAMP level stimulates cAMP-dependent kinase (PKA)
(Figure 2), which, in turn, activates several pathways through calcium channels, potassium
channels, cAMP responsive element-binding (CREB), mitógeno-activated protein kinase
(MAPK) and phospholipase C (PLC) activation [23, 54].
The A2A receptor structure is very similar to other adenosine receptors. However, it differs in
the four disulfide links observed at the extracellular level, which are critical for the packing
and stabilization of the restricted conformation of the seven transmembrane helices. Another
difference concerns the A2A receptor length of the C-terminal region, which consists of
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approximately 120 residues [55]. In 1995, Kim et al. published the results of site directed
mutagenesis experiments on A2A receptors [56], revealing the essential role of some residues
for ligand interaction, particularly Phe182 (5.43), Asn253 (6.55), Ile274 (7.39), and Ser281 (7.46).
The key role of His250 (6.52), Ser277 (7.42) and His278 (7.43) was also confirmed. After 1995,
several mutagenesis studies revealed some of the amino acids residues involved in direct or
indirect interaction with ligands or in allosteric regulation. It was observed that the conserved
Glu 1.39 is critical for agonist but not antagonist binding [57, 58]. Glu13 (1.39) and His278 (7.43)
were found to be critical for the allosteric regulation of A2A receptors [59], and Gln89 (3.37) was
suggested to play an indirect role in ligand binding, while Ser281 (7.46) mutation to asparagine
improved agonist affinity [60]. Additional studies were carried out to analyze the role of loop
residues of A2A receptors, revealing the importance of Glu151 and Glu169 (EL2) for ligand
binding [61]. Unlike A1 receptors, there is a considerable consensus regarding the effects of
A2A receptors on the inflammatory response. A broad range of investigations using in vivo and/
or in vitro approaches have provided evidence that A2A receptor activation limits inflammation
and tissue damage, therefore playing an anti-inflammatory role [13, 31]. The A2A receptor
signaling in suppressing inflammation is related to cAMP-increased levels, which also have a
well-known immunosuppressive effect on immune cells. Corroborating these data, the fact
that A2A receptors are expressed on most cells of the immune system is crucial to its anti-
inflammatory properties [62]. Thus, the anti-inflammatory properties of these receptors are
due, at least in part, to the prevention of the activation of effector cells of the immune system.
For example, they may prevent neutrophil migration and interfere in the activity of proteins
on the surface of neutrophils and endothelial cells that are crucial to the adhesion and
migration of the former into the inflammatory site. In these sense, A2A receptor activation
inhibits the adherence of N-formyl methionyl-leucyl-phenylalanine (fMLP)-activated neutro‐
phils to the endothelium [63] and downregulates Mac-1 [64], β2-integrin [65] and L-selectin
[66]. Furthermore, activation of the A2A receptors also downregulates the activity of other
endothelial cell surface proteins, including vascular cell adhesion molecule-1 (VCAM-1),
intracellular adhesion molecule-1 (ICAM-1) [67], alpha 4/beta 1 integrin (VLA4) [68] and
platelet cell adhesion molecule [69]. On the other hand, the anti-inflammatory properties
resulting from A2A receptor activation are due to the reduction of the release of inflammatory
mediators such as IL-12, INFγ, TNF-α, and IL-4 from important immunomodulatory cells such
as neutrophils, monocytes, dendritic cells and T lymphocytes [70, 71].
Many of the anti-inflammatory effects of A2A receptors are mediated by adenosine itself. It is
known that inflammatory tissue damage is accompanied by the accumulation of extracellular
adenosine in inflamed sites due to its release from non-immune and immune cells. Because
endogenous adenosine levels are elevated during an inflammatory process and endogenous
adenosine can activate A2A receptors to attenuate inflammation and tissue damage, strategies
that aim to foment adenosine production and increase its availability to activate A2A receptors
present extraordinary anti-inflammatory potential. In this regard, an interesting study
demonstrated that the immunosuppressive effects of activated Treg lymphocytes could be in
part related to adenosine production in the extracellular environment through both CD39 (an
ectonucleoside triphosphate diphosphohydrolase that converts ATP and ADP to AMP) and
CD73 (an ectonucleoside that converts AMP to adenosine) expressed on the surface of these
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cells. Moreover, the Treg immunosuppressive effects have been shown to be modulated by
A2A receptors [72]. In a model of ischemia reperfusion liver injury, treatment with ATL146e (4-
(3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-
prop-2-ynyl)- cyclohexanecarboxylic acid methyl ester), an agonist of A2A receptors, was
associated with decreased inflammation and protection from liver damage. When A2A receptor
knockout mice were subjected to the same insult, the effectiveness of ATL146e was lost [73].
Later, similar approaches showed the protective effect of the A2A receptor in models of
myocardial infarction, acute lung injury and spinal cord compression injury [74] [75, 76].
In another study, the same A2A receptor agonist, ATL146e, was associated with decreased
leukocyte infiltration, inflammatory mediator production and necrosis in a model of inflam‐
matory bowel disease [77]. In a model of LPS-induced lung injury, treatment with the A2A
receptor agonist ATL202 was associated with decreased recruitment of neutrophils to the lung
together with reduced cytokine levels and pulmonary edema, whereas A2A receptor knockout
mice treated with LPS showed an increase in neutrophil recruitment [75]. In a mouse model
of allergic lung inflammation, treatment with an A2A receptor (CGS-21680) agonist resulted in
diminished pulmonary inflammation [78]. On the other hand, A2A receptor knockout mice have
been shown to have higher lung inflammation compared to wild-type mice [79].
4.3. A2B adenosine receptors
The A2B receptor couples to Gi-type G proteins, leading to the inhibition of adenylate cyclase
upon receptor activation [80]. In some cell systems, such as HEK-293 and HMC-1 mast cells,
A2B receptors are also coupled to phospholipase C via the action of Gq proteins in increasing
intracellular Ca2+ levels [81-83]. The A2B receptor has also been described to be involved in the
ERK1/2 [80, 83, 84] and p38 MAPK pathways in mast cells (Figure 2) [85]. Furthermore, a link
between A2B receptor signaling and the arachidonic acid signal transduction pathway leading
to vasoconstriction has been described [83, 86]. Among the four adenosine receptors, A2B is the
least well characterized receptor, mainly due to the lack of suitably specific ligands [87].
The A2B receptor has low affinity for most agonists, so only some agonists are useful, including
the non-selective and related adenosine derivative NECA [88] and the highly selective A2B
agonist BAY60-6583 [89]. Conversely, highly selective A2B antagonists have been developed,
such CVT-6883 and an A2B-specific antagonist radioligand, [3H]PSB-603, which has high
potency and specificity across species, including rodents and humans [90]. The A2B receptors
have a closely related structure to A2A receptors, and sequence analysis of the human A2A and
A2B receptors show an overall identity of 58% and a similarity of 73%. The most conserved
residues are found within the seven transmembrane domains. [83]. In contrast to the A2A
receptor, the A2B receptor possesses the longest extracellular loop 2 (ECL2) of all four adenosine
receptor subtypes, with four cysteine residues – the highest number found in any GPCR – of
which three (C154, C167, C171) are homologous to the three (C146, C159, C166) found in the
A2A receptor [83]. These cysteine residues are involved in disulfide bonds formed between the
ECL and transmembrane domains (TM) of GPCRs and have been reported to play an important
role in ligand binding affinity and receptor stability and function.
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Studies of mutagenesis, X-ray receptor analysis and radioligand binding have shown that C78
in transmembrane domain 3 (TMD3) and C171 in ECL2 form an important disulfide bond
related to ligand-binding affinity and receptor expression levels [83, 91, 92]. In agreement with
these data, in a mutagenesis model in which the complete ECL2 of human A2B was exchanged
for the ECL2 of the A2A receptor, the mutant A2B (ECL2-A2A) receptor mice had increased
affinity and selectivity for A2B agonists and antagonists as well as receptor-mediated cAMP
accumulation, indicating that ECL2 is a ligand binding site [93]. ECL2 also seems to contribute
to the low affinity of ligands to A2B receptors because it has been shown to have between 4 and
10 more amino acids than A2A receptors. The longer ECL2 may, in some cases, partially block
the entrance of ligands into the binding pocket and explain why A2B receptors typically show
lower affinity for adenosine and adenosine derivatives (agonists) than A2A receptors, which
have a shorter ECL2, which may facilitate the entrance of ligands to the binding pocket [83].
In addition, residues Thr42, Val54 (2.51) and Phe84 (3.31) are also involved in the binding site;
Figure 2. A brief summary of the role of the purinergic system in inflammation. A1, adenosine A1 receptor; A2A, adeno‐
sine A2A receptor; A2B, adenosine A2B receptor; A3, adenosine A3 receptor; AC, adenylate cyclase; cAMP, cyclic adeno‐
sine monophosphate; ERK1/2, extracellular signal-regulated kinases 1 and 2; IP3, inositol triphosphate; MAPK,
mitogen-activated protein kinase; PKB, protein kinase B; PLC, phospholipase C; PI3K, Phosphatidylinositide 3-kinase;
ATP, adenosine triphosphate; AMP, adenosine monophosphate; HXT, hypoxanthine; AK, adenosine kinase; ADA, ade‐
nosine deaminase; PNP, purine nucleoside phosphorylase; ENTs, equilibrate nucleoside transporters; CD 39, ectonu‐
cleoside triphosphate diphosphohydrolase; Inhibition → ; Activation - - →
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mutation to alanine, leucine or serine, respectively, decreased agonist binding [94]. As
mentioned above, in many tissues, A2B receptors are considered low-affinity receptors with
mostly low expression levels, so adenosine needs to reach higher concentrations to activate
them [83, 95].
During hypoxia, a critical role of HIF-1 in the transcriptional induction of the adenosine A2B
receptor has been suggested. In such conditions, as in A2B-/- receptor mice, the presence of
A2B receptors attenuates hypoxia-induced increases in vascular leakage, mainly in the lungs,
a protective effect [95]. Accordingly, Yang and colleagues reported that A2B-null mice present
augmentation of proinflammatory cytokine levels, such as TNF-α, upregulation of vascular
adhesion proteins and leukocyte migration in response to LPS-induced acute inflammation.
Conversely, in adenosine-deficient mice and bleomycin-induced lung inflammation, the
antagonist CVT-6883 attenuated pulmonary inflammation [96]. Moreover, A2B activation
resulted in an increase in IL-8 [85], IL-1beta, IL-3, IL-4, IL-13 and IgE leading to mast cell and
Th2 and B lymphocyte activation [97]. Mice treated with CVT-6883 and MRS-1754 or A2B-null
mice developed less severe experimental autoimmune encephalomyelitis (EAE) with reduced
IL-6 release and Th17 cell differentiation [98].
In spite of the structural similarity, adenosine has been recognized as the natural ligand of
A2B receptors, but inosine was not [99, 100]. However, a recent study conducted by our group
has shown evidence that inosine can reduce both acute pleural inflammation and allergic lung
inflammation through a mechanism that involves both A2A and A2B receptors, suggesting a
regulatory role of inosine and A2 in these process [11, 101]. Taking into account the lack of
information about the A2B receptor and its involvement in several inflammatory diseases, it
may be a candidate target for future therapeutic intervention
4.4. A3 adenosine receptors
Studies have demonstrated that both adenosine and inosine can activate A3 receptors in vitro
and therefore can directly modulate its activation and biological effects [99, 100]. Similar to
other adenosine receptors, the A3 receptors is a GPCR with seven transmembrane domains
(TM). It is coupled to classical second-messenger pathways such as inhibition of adenylyl
cyclase, stimulation of PLC and calcium mobilization [33, 102-104].
In the heart, A3 mediates cardioprotective effects through the activation of KATP channels that
are coupled to RhoA–phospholipase D signaling, mediating the protection of cardiac myocytes
from ischemia [104]. With regard to cardiac protection, signaling through cAMP response
element-binding protein (CREB)-Bcl2 pathways after A3 receptor activation has also been
described [104]. In addition, like other adenosine receptors, A3 receptors are coupled to MAPK
and lead to stimulation of extracellular signal-regulated kinases (ERK1/2), which relates A3
receptor activation to cell growth, survival, death and differentiation [33, 80].
A3 receptor activation in melanoma cells stimulates PI3K-dependent phosphorylation of
protein kinase B (PKB/Akt), leading to the reduction of basal levels of ERK1/2 phosphorylation,
which in turn inhibits cell proliferation (Figure 2) [105]. Consistent with these data, treatment
with IB-MECA induced inhibition of tumor growth [33, 104], although in the hypoxic condi‐
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tions that occur in solid tumors, A3 activation mediates angiogenesis and cell survival through
increased HIF-1 α and VEGF production [106]. Moreover, the A3 receptor is involved in
adenosine and inosine induced-mast cell degranulation [99, 107]; inhibition of endotoxin-
induced neutrophil granulation and TNF-α production [108, 109]; reduction of T cell tumori‐
cidal activity and enhancement of natural killer cell cytotoxicity [104]; reduction of neuropathic
pain [110]; and augmentation of bone marrow cells proliferation favoring myeloprotection
[111]. One of the characteristics of the A3 receptor is the rapid (within a few minutes) desen‐
sitization through phosphorylation by G-protein-coupled receptor kinase 2 (GRK2) at the
intracellular threonine residues within the C-terminal domain after exposure to an agonist,
which can limit the agonist’s effect [112-114].
A3 receptors exhibit the lowest degree of identity among species compared with other
adenosine receptor subtypes [115]. In a study that used a combination of mutagenesis,
radioligand binding, functional activity and molecular modeling approaches, a mutation of
TMD3 His95 (3.37), which is conserved in A3 receptors in various species including humans,
sheep and rats, resulted in a decreased affinity of agonists and antagonists and is therefore
considered critical to ligand binding. The same was observed when His272 (7.43) and Asn250
(6.55) were mutated. Moreover, residues Tyr243 (6.48) and Lys152 (ECL2) were needed only
for antagonist binding [115], and Trp243 (TM6) is involved in the functional activation of the
A3 receptor based on the impairment of the coupling of the receptor to the G protein in the
Trp243 mutant [115, 116]. Furthermore, molecular modeling suggested that Trp243 is in the
binding pocket and might occupy a strategic position as a switch in the TM6-mediated
structural transition from the resting to the active state [115]. Given the involvement of A3
receptors in important pathological process, as described above, several studies evaluating the
structure-activity relationships of agonists and antagonists with A3 receptors have been
conducted to identify new potential drugs for the treatment of deleterious diseases.
5. Adenosine and inosine regulation on leukocyte function
The action of adenosine and inosine on the immune system is determined by their bioavaila‐
bility and adenosine receptor expression in immune cells. The rapid release of adenosine in
response to tissue-disturbing stimuli such as hypoxia, ischemia, inflammation or trauma and
the rapid conversion of adenosine into inosine have been reported to modulate the function
of leukocytes, a basic constituent of immune system [117]. In this section, we discuss adenosine
and inosine modulation of immune cells and the corresponding involvement of adenosine
receptors.
Neutrophils are the first immune cells recruited to inflamed sites by a combination of chemo‐
attractant cytokines and adhesive interactions between leukocytes and the vascular endothe‐
lium [118, 119]. Adenosine mainly acts on A2A receptors, signaling through cAMP-PKA-
dependent pathways. It decreases neutrophil activation, neutrophil-mediated injury to
endothelial cells, production of reactive oxygen species, PAF, and leukotriene B4, secretion of
cytokines such as TNF-α and chemokines such as MIP-1alpha/CCL3, MIP-1beta/CCL4,
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MIP-2alpha/CXCL2 and MIP-3alpha/CCL20 and expression of adhesion molecules such as
selectins and integrins [31, 120-128]. Similar to adenosine, inosine also interferes with neutro‐
phil activation by blocking formyl-Met-Leu-Phe-induced superoxide generation [31, 100],
neutrophil migration and release of the proinflammatory cytokines TNF-α and IL-1β during
acute inflammation, acting through A2A and A2B receptors [11]. A3 and A2A receptors are
involved in the reduction of superoxide anion generation [127, 129]. A3 receptors can also direct
neutrophil migration [130]. Interestingly, the adenosine interaction with A1 and A3 receptors
induces G-CSF production, which leads to a stimulatory effect on bone marrow cells, suggest‐
ing that adenosine is a chemoprotective agent that could restore the number of leukocytes and
neutrophils to normal levels after chemotherapy [131].
Macrophages and dendritic cells are phagocytes that are widely dispersed throughout the
body at portals of microorganism entry [31]. They initiate an effective innate immune response
against microbes by recognizing pathogen-associated molecular patterns (PAMPs) through
pattern-recognition receptors (PRRs) [119, 132]. This response involves pathogen processing
and is regulated by the secretion of several cytokines and activation of lymphocytes and other
immune cells.
In this context, studies have demonstrated that adenosine inhibited TNF-α, IL-6 and IL-8
release from macrophages stimulated with thioglycollate or LPS via A2A receptors, although
the A2B receptors seems to play an underlying inhibitory role that may contribute to anti-
inflammatory action [133, 134]. Some studies have demonstrated that adenosine can increase
IL-10 production and release through a mechanism involving adenosine A2A receptor-
CEBPβ axis activation [135]. The augmentation of the production of IL-10 and the decrease in
systemic endotoxin-induced levels of TNF-α, IL-12, MIP-1α and IFN-γ have also been ascribed
to inosine [136]. Current data have shown that activation of both A2A and A3 receptors inhibited
IFN-γ and IL-12 release after TLR-4 stimulation by LPS [137-139]. Adenosine and inosine were
described to decrease M1 activation and the release of mediators, reducing Th1 response, by
interfering with TLR-4 activation. Moreover, there is growing evidence that A2A receptor
activation also reduces the TLR-2, 3, 7, and 9 responses in M1 macrophages, upregulating
VEGF and IL-10 expression and therefore polarizing macrophages into an M2-like phenotype,
called M2d, which favors an angiogenic switch and plays a protective role in ischemia [70, 140].
Adenosine also interferes with mature dendritic cell stimulation by producing a dose-
dependent inhibition of TNF-α and IL-12 release, whereas it enhanced the secretion of IL-10,
preventing tissue injury mediated by innate immune mediators during overwhelming
immune response [141]. Furthermore, dendritic cells matured in the presence of adenosine
had a reduced capacity to induce T helper 1 (Th1) polarization of naive CD4+ T lymphocytes,
evidence that adenosine diminishes the capacity of dendritic cells (DCs) to initiate and amplify
Th1 immune responses [141].
Mast cells are resident in all normal tissues, where they are believed to play an important role
in tissue homeostasis, wound healing and host defense, particularly in terms of bacterial
infection. When activated, they secrete the autacoid mediators histamine, prostaglandin
(PG)D2 and leukotriene (LT)C4, which contribute to the pathophysiology of many diverse
diseases including rhinitis and asthma [142-144].
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Rodent and human mast cells express the A2A, A2B and A3 receptors [145-149]. It has been
reported that adenosine and inosine binding to A3 receptors expressed in mast cell membranes
induces degranulation and release of vasoactive mediators [99, 107]. Accordingly, the release
of reactive mediators following A3 activation in mast cells is directly related to the broncho‐
constrictor effects observed after topical administration of adenosine in the airways of patients
with asthma and chronic obstructive pulmonary disease [109, 150]. In contrast, inosine has no
effect on airway caliber, indicating that bronchoconstriction is a specific response to adenosine
[151]. Engagement of the A3 receptors on rodent mast cells mediates degranulation and cell
migration through a mechanism that involves phosphoinositide 3-kinase (PI3K) or protein C
kinase (PKC) activation and an increase in intracellular Ca2+ [146, 147]. Moreover, A1 and A2B
receptor activation has been related to the release of histamine, IL-8, IL-4 and IL-13 by mouse
and human mast cells [97, 152-154]. In contrast to the A1 and A2B receptors, A2A activation results
in the suppression of histamine and tryptase release from human mast cells [155]. A2A and
A2B receptors provide a balanced control mechanism for mast cell activation. It is possible that
at low concentrations of adenosine, only the ‘off’ signal provided by the engagement of the
higher affinity A2A receptors prevails, thus downregulating mast-cell mediator release.
Conversely, in situations in which high concentrations of adenosine are reached, such as in
asthma and COPD [156], the low-affinity A2B receptor becomes activated, resulting in signifi‐
cant mast cell degranulation [108, 109, 157]. Although the effects of adenosine regarding mast
cell activation are well described, there is a lack of information regarding the effects of inosine
on the activation of the A3 receptor. Recently, a study from our group suggested that inosine
can activate A2A, A2B and A3 receptors and decrease mast cell migration during allergic
pulmonary inflammation, suggesting that inosine can modulate allergic inflammation [101].
Lymphocytes cells play a vital role in the induction of adaptive immune responses and in
steering them toward particular effector phenotypes [119]. Several pieces of evidence suggest
that adenosine and inosine generated in the site of inflammation can modulate lymphocyte
function [23, 24, 28]. Experimental data demonstrated that in ConA-induced liver injury (an
in vivo model mediated by T cells), inosine inhibited hepatocyte apoptosis and reduced the
accumulation of proinflammatory cytokines (e.g., TNF-α) and alanine transaminase in A3+/+
but not A3-/- or A2-/- mice, suggesting the endogenous inosine can influence inflammatory
responses and indicating the importance of A3 receptors in controlling liver injury [28].
The extracellular adenosine generated in inflammatory or hypoxic environments affects
regulatory T cell lymphocytes (Treg) through the activation of A2A receptors. Treg cells are a
specialized population of CD4+ T cells implicated in the regulation of immune responses,
maintenance of immunological self-tolerance and protection from excessive inflammatory
damage [24, 158]. A2A receptor stimulation expanded the Treg population [159] coordinated
by coexpressed CD39 ecto-ATPase/ADPase and CD73 ecto-5’-nucleotidase and generating
adenosine pericellularly [72, 160]. The CD39- and CD73-mediated generation of extracellular
adenosine might provide Treg cells with the capacity to directly inhibit DC and T effector cells
by activating their respective cAMP-elevating A2A receptors [160]. Consistent with these data,
the A2A receptor has been described to suppress the development of T-cell receptor (TCR) -
stimulated naive T cells into both Th1 and Th2 cells [135], interfering with early development
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as well as the late effector stages of Th1- and Th2-cell responses [135]. The activation of A2B
receptors seems to indirectly inhibit Th17 activation. A recent study using EAE in mice
indicated that blocking A2B receptors with specific antagonists, such as CVT-6883 and
MRS-1754, alleviated the clinical symptoms of EAE and protected the CNS from immune
system-mediated damage. Confirming this hypothesis, the deletion or blockade of A2B
receptors inhibited Th17 cell differentiation by blocking IL-6 production from APCs such as
dendritic cells. The activation of phospholipase Cβ-protein kinase C and p38 MAPK pathways
was found to be involved in A2B-mediated IL-6 production, suggesting A2B as a target for the
development of anti-multiple sclerosis drugs and indicating that adenosine might participate
in regulation of this pathology [98].
6. Overall effect of adenosine and inosine on inflammatory diseases
6.1. Asthma and COPD
A great deal of evidence suggests that adenosine plays a detrimental role in asthma and COPD
and perhaps other chronic airway disorders [161]. The potential role of adenosine triphosphate
and adenosine in the pathogenesis of asthma and COPD has been supported by the broncho‐
constrictor effects observed after their topical administration in the airways of patients with
these diseases and the lack of reaction in healthy subjects [150, 162-164]. However, there is
some controversy about the role of adenosine during allergic reactions in the airways, such as
asthma. When administrated topically, as mentioned above, it seems to trigger airway
hyperactivity, but the administration of non-selective and selective agonists of different
adenosine receptors can suppress (such as adenosine A2A receptors) [165-167] or contribute
with airway allergic inflammation, as described below.
Treatment with CGS21860, a selective A2A receptor agonist, reduced the number of leukocytes
in bronchoalveolar lavage fluid, protein content and eosinophil peroxidase activity in Brown
Norway rats immunized and challenged with OVA, a compound similar to the glucocorticos‐
teroid budesonide [165]. Moreover, treatment with NECA, a non-selective adenosine A2
receptor agonist, reduced the total leukocyte infiltration and eosinophilia in a model of allergic
airway inflammation [166]. Interestingly, inosine but not adenosine was described to reduce
leukocyte infiltration into the lungs, Th2 pro-inflammatory cytokine levels and improve
pulmonary mechanics in OVA-induced airway inflammation through a mechanism involving
the A2A and A3 receptors [101]. Consistent with these data, inosine and its stable analogue
INO-2002 were described to reduce LPS-induced airway inflammation [26, 168]. Several
studies have hypothesized that the bronchial response to adenosine observed in asthma and
COPD in humans can be attributed to an indirect mechanism involving mast cell activation,
likely via A2B or A3 receptors and the release of mediators such as histamine and leukotriene
(LT)C4 [109, 150, 169]. These are low-affinity receptors that can modulate the deleterious effect
of high concentrations of adenosine in chronic airways diseases [108, 109, 157]. Likely,
adenosine signaling through the A2B receptor also plays a role in asthma development,
promoting the upregulation of pro-inflammatory cytokines, leukocyte migration and airway
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remodeling (Figure 3) [170, 171]. Other studies have described a pro-fibrotic role for A2B
receptor signaling, which results in the differentiation of human pulmonary fibroblasts into
collagen-producing myofibroblasts, increasing the production of the pro-fibrotic molecule
fibronectin in alveolar epithelial cells [147, 161, 172]. These data demonstrate the potential
involvement of A2B receptors in the remodeling and fibrosis observed in asthma and COPD.
Although the A3 receptors appear to reduce inflammation and eosinophil activation in
humans, in mice, A3 activation induces mast cell degranulation and increases inflammation,
activating eosinophils and mucus production [161, 173].
The literature data describes differences in mast cell expression between rodents and humans
and maybe it can explain the different effects of adenosine in modulating these cells during
asthma and allergy. The adenosine A3 receptor that was expressed in mast cells in rodents
[174], have recently been described to be expressed in human lung mast cells [175]. While the
expression of adenosine A2A and A2B receptors in rats was not described; in mice, both were
expressed in bone marrow derived mast cells. The A2A receptors were also described in cardiac
mast cells, in mice [174]. In humans, both receptors have been described in lung mast cells and
in human mast cells line HMC-1 [174, 176]. The adenosine A1 receptor were not described to
be expressed in mice and humans but recent data have shown that agonists of adenosine A1
receptor can potenciate human cultured mast cell activation, suggesting a modulatory effect
[152, 177, 178].
The A1 receptor is also described to have pro or anti-inflammatory effects on airway inflam‐
mation. Treatment with an A1 receptor antagonist [179] or with antisense oligodeoxynucleo‐
tides targeting this receptor reduced the bronchoconstrictor responses in an allergic rabbit
model [180]. Conversely, in knockout A1-/- mice, an increase in transmigration of polymor‐
phonuclear cells and microvascular permeability in comparison to wild type mice was
observed in a model of LPS-induced lung injury, suggesting a possible protective effect of the
A1 receptor in airways [181]. The engagement of adenosine receptors on inflammatory and
pulmonary cells appears to play an important role in regulating chronic lung disorders such
as asthma and COPD, so the complete and full characterization of adenosine receptor subtype
distribution in the airways and their specific role in the response to adenosine and inosine in
health and disease is important for the development of new therapies to treat asthma and
COPD [161].
6.2. Skin inflammation and wound healing
The skin is a highly specific immune defense organ. Physical, chemical or immune-specific
insults rapidly evoke cellular responses, characterized by the increased expression of a wide
range of pro-inflammatory mediators [182]. Controlling the extent of an immune response is
thus a major challenge for maintaining skin integrity, which is of paramount importance for
host survival [183]. In this context, several lines of evidence have shown that adenosine and
adenosine receptors contribute to the regulation of skin inflammation.
A recent study showed that activated Treg cells can produce adenosine in a CD39-dependent
manner and abrogated the ear-swelling reaction induced by 2,4,6-trinitro-1-chlorobenzene
(TNCB), indicating a role of adenosine in the Treg cell–induced suppression of contact
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hypersensitivity responses. Moreover, the same study demonstrated that adenosine’s effects
involve the impairment of effector T cell adhesion to inflamed endothelium and downregu‐
lation of E- and P- selectin in the vascular endothelium [184]. A complementary study of IL-10-
deficient (IL-10-/-) Tregs showed impaired adenosine production, which contributes with their
inability to suppress contact hypersensitivity responses, indicating that the reduced suppres‐
sive effects observed may not be exclusively attributable to the lack of IL-10 production [185].
Several lines of evidence indicated that adenosine’s effects on skin are mediated by the
activation of adenosine receptors.
The activation of A1 receptors has been demonstrated to decrease the numbers of circulating
neutrophil granulocytes and ear swelling in a model of stress-induced contact hypersensitivity
response [186]. In addition to receptor A1 activation, activation of receptor A2A was described
to reduce leukocyte activation and to prevent ischemia reperfusion wound formation in a rat
model of a pressure ulcer [187]. Evidence from experiments performed on A2A receptor
knockout mice and with CGS21680 demonstrated that the A2A receptor is the main adenosine
receptor subtype involved in wound healing [149, 188]. In addition, histological analysis of
mice treated with the same agonist showed faster re-epithelialization and increased matrix
deposition, fibroblast density and vascularity in the granulation tissue of the agonist treated
wounds as soon as 3 days after injury [188]. A study from the same group revealed that
treatment of human microvascular endothelial cells (HMVEC) with the selective A2A receptor
agonists CGS21680 and MRE0094 (Sonedenoson) favors vascular tube formation by cultured
HMVEC and downregulated the antiangiogenic matrix protein thrombospondin 1 (TSP1)
secretion by these cells, indicating that A2A activation induces angiogenesis [189]. Furthermore,
treatment with MRE0094 increased the rate of wound closure in comparison to recombinant
human platelet-derived growth factor (Becaplermin gel), an agent currently used to promote
the healing of diabetic ulcers, indicating the importance of A2A receptors in wound healing
[190]. Moreover, the A2A and A2B receptors were described to contribute to tissue formation
because their activation leads to enhanced fibroblast and endothelial cell migration [191].
Adenosine seems to have a fibrogenic role in the skin. A study using ADA-deficient mice
reported a direct fibrogenic effect of adenosine on the skin, and pharmacological treatment
with the A2A receptor antagonist ZM-241385 prevented the development of dermal fibrosis by
reducing dermal collagen content and the expression of profibrotic cytokines and growth
factors (Figure 3) [192]. The data mentioned above are interesting and strongly suggest that
adenosine and A2A receptors have important modulatory effects in skin homeostasis. Although
several studies have shown a role for adenosine in the skin, nothing has been found regarding
a role for inosine. Additional studies addressing the real role of the purinergic system in the
skin would be extremely useful to improving wound management and care, as well as
controlling chronic inflammatory diseases in skin.
6.3. Arthritis
Arthritis is the term used to designate a particular pathological condition that encompasses a
constellation of more than 100 diseases, among which osteoarthritis (OA) and rheumatoid
arthritis (RA) stand out. OA is the most common adult joint disease and is increasing in
Pharmacology of Adenosine Receptors and Their Signaling Role in Immunity and Inflammation
http://dx.doi.org/10.5772/57206
101
frequency and severity, with an estimated US prevalence of more than 25 million affected
adults [193]. It is characterized by gradual loss of articular cartilage and is therefore being
considered a slowly progressing degenerative disease. The etiology of arthritis involves
biochemical and genetic factors as well as repetitive mechanical injury, which has been
proposed as the critical mechanisms contributing to alterations in the normal functional
activities of chondrocytes, the main cellular component of hyaline cartilage, disrupting
chondrocyte–matrix associations and culminating in the initiation and progression of OA
[194].
In early OA, a transient proliferative chondrocytes response (clonal growth) occurs along with
increased synthesis of the cartilage matrix as an early repair attempt and increased synthesis
of catabolic cytokines (such as IL-1, TNF-α and IL-18) and matrix-degrading enzymes (such
as metalloproteinases, especially collagenases, and aggrecanases). Fibroblast- and macro‐
phage-like cells in the synovia also generated catabolic cytokines in response to breakdown
products from the damaged cartilage. All these events contribute greatly to the local loss of
proteoglycans and cleavage of type II collagen, which initially occurs at the cartilage surface,
contributing to water content increases and loss of tensile strength in the cartilage matrix as
the lesion progresses [195, 196]. It is characterized by several inflammatory cascades, which
all lead towards a final common pathway in which persistent synovial inflammation and
associated damage to articular cartilage and underlying bone are present [197].
One inflammatory cascade that deserves attention in the pathogenesis of RA is the overpro‐
duction and overexpression of TNF-α. Interactions between T and B lymphocytes, synovial-
like fibroblasts and macrophages are likely to be involved in TNF-α and IL-6 overproduction,
contributing to both synovial inflammation and joint destruction [198]. In addition to inflam‐
matory cytokines, rheumatoid factors are key pathogenic markers of classic RA. In this case,
the immunoglobulins IgM and IgA are directed against the Fc fragment of immunoglobulin
IgG, resulting in the formation of immune complexes, which are able to activate the comple‐
ment system, initiating an immune response [199]. Adenosine has a known therapeutic
potential against inflammatory joint diseases; studies have demonstrated its ability to limit
synoviocyte [200] and chondrocyte [201] inflammatory responses and to minimize articular
damage in adjuvant-induced models of arthritis in rats [202].
In an interesting study, Tesch and colleagues demonstrated that endogenously produced
adenosine regulates articular cartilage matrix homeostasis in vitro. In this study, authors
showed that the depletion of endogenous adenosine through exposure to adenosine deami‐
nase (ADA) in cartilage explants resulted in cartilage matrix degradation, involving matrix
metalloproteinases-3 and -13 (MMP-3, MMP-13), prostaglandin E2 (PGE2), and nitric oxide
(NO) release. In addition to these data, this study suggested that endogenously released
adenosine can regulate chondrocyte production of matrix-degrading enzymes and matrix loss,
an effect believed to be in part mediated via A2A receptors, because N6-[2-(3,5-dimethoxyphen‐
yl)-ethyl]adenosine (DPMA, an A2A receptor selective agonist) was able to prevent the release
of PGE2, NO and glycosaminoglycan (GAG) (Figure 3) [203]. Another in vitro study demon‐
strated that adenosine, N6-methyladenosine (a substituted adenosine derivative that is
resistant to breakdown by adenosine deaminase), DPMA and 5′-N-ethylcarboxamidoadeno‐
Pharmacology and Therapeutics102
sine (NECA, a non-selective adenosine receptor agonist) suppressed NO production by LPS-
stimulated equine chondrocytes [201]. The addition of exogenous adenosine and erythro-9-(2-
Hydroxy-3-nonyl) adenine hydrochloride (EHNA, an adenosine deaminase inhibitor) further
suppressed NO production by LPS-stimulated chondrocytes [201]. These two studies clearly
demonstrate the protective effect of adenosine against degradation of articular cartilage in
vitro, suggesting its potential to prevent joint damage and hence its effectiveness in the
prevention of joint diseases such as osteoarthritis.
In the second half of the 1980s, remarkable attention was focused on investigating the role
played by ADA in RA pathophysiology, which provided the first evidence of the role of
adenosine in RA. These studies showed increased levels of ADA activity in the synovial fluid
from patients with seropositive rheumatoid arthritis, suggesting a local release of this catabolic
enzyme by cells within joints [204]. Subsequent investigations were aimed at characterizing
the activities of different ADA isoforms in tissues, cell homogenates and serum samples
obtained from patients with rheumatic disorders. The highest level of enzyme activity was
found in lymphocytes and monocytes from patients with rheumatoid arthritis, and ADA-2
was the isoform specifically expressed in monocytes [205]. Iwaki-Egawa and colleagues
observed a significant positive correlation between high activity of ADA isoforms in the
synovial fluid of rheumatic patients and metalloproteinase-9 (MMP-9), an enzyme critical to
the regulation of the cell matrix composition [206]. These results suggest that the high activity
of ADA in the synovial fluid of patients with RA and consequently the reduction in local levels
of adenosine are directly related to the development and maintenance of RA. In support of
this hypothesis, Forrest and colleagues demonstrated that adenosine is able to suppress the
elevated levels of proinflammatory cytokines such as TNF-α and IL-1β in RA patients and that
this effect appears to be mediated by adenosine receptors [207].
Recent studies have shown adenosine A3 receptor upregulation in RA patients, suggesting the
potential of this receptor as a therapeutic target. In agreement with these results, after oral
treatment with CF101, a selective A3 receptor agonist, a marked decrease in RA clinical
manifestations including inflammation, pannus formation, cartilage destruction and bone
reabsorption and lysis was observed [208].
6.4. Ischemia
Ischemia is defined as a lack of blood supply to an organ or tissue, resulting in cellular oxygen
deprivation. Although ischemia itself is a serious condition, the phenomenon that seems to be
the definitive treatment for ischemia, reperfusion of the ischemic tissue, can promote further
tissue injury, especially after prolonged ischemia [209]. Thus, the tissue can be injured by both
ischemic and reperfusion processes and can be defined as ischemia reperfusion (IR) injury. IR
injury involves a complex cascade of events including oxidative stress, inflammation and
interactions among many cell types [209]. Furthermore, it has widespread clinical relevance
and is encountered in a variety of surgical settings (e.g., transplantation, cardiopulmonary
bypass and aneurysm repair) as well as non-surgical settings (e.g., myocardial infarction,
stroke, hemorrhage, trauma and shock).
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One of the potentially most striking features of IR injury involves the generation of reactive
oxygen species (ROS) (e.g., superoxide, peroxynitrite, hydrogen peroxide, and hydroxyl
radical) [210, 211], especially during reperfusion of ischemic tissue, which, in turn, initiates an
inflammatory cascade resulting in direct oxidative injury to cells and stimulation of pro-
inflammatory mediators such as cytokines, chemokines and cell-adhesion molecules. Briefly,
circulating and resident leukocytes, such as neutrophils, lymphocytes and macrophages as
well as tissue resident cells, such as dendritic cells, contribute to the immune response to IR
injury, particularly infiltrating neutrophils, which can impose significant tissue injury through
ROS generation and further release of cytokines and proteases [212].
Strong evidence has indicated that cellular responses to hypoxia include robust increases in
extracellular adenosine and signaling events through adenosine receptors. The hypoxic
adenosine response in acute injury settings is able to promote tissue adaptation during
hypoxia, including restoration of normal oxygen levels, enhancing metabolic ischemia
tolerance and dampening inflammation [213]. Preclinical studies have shown that adenosine
signaling is beneficial in ischemic acute injury in the lung [214, 215], kidney [216], heart [217],
gastrointestinal track [218] and liver [73]. Some studies have demonstrated that chronic
elevations of adenosine can contribute to tissue fibrosis in different organs including the lungs
[170, 219], liver [220], skin [221], kidney [222] and following transplants [223]. Studies using
CD39 and CD73 knockout mice, which lack both the enzyme that converts ATP to ADP/AMP
and the enzyme that converts AMP to adenosine, and inhibitors of these enzymes demon‐
strated enhanced inflammation and tissue injury in models of hypoxia and ischemic injury [6,
224] concurrent with reduced production of adenosine. These results suggest that elevated
extracellular levels of adenosine may display a protective effect in models of hypoxia and
ischemia injury. An interesting strategy used to enhance extracellular levels of adenosine is
the prevention of adenosine uptake by equilibrate nucleoside transporters (ENTs) [225].
Recently, Grenz and colleagues demonstrated that treatment with dipyridamole, an inhibitor
of ENTs, led to increased adenosine levels in association with tissue protection in a mouse
model of ischemic acute kidney injury [226]. Furthermore, genetic deletion of ENTs resulted
in selective protection in ENT1-/- mice. A more detailed analysis using adenosine receptor-
knockout mice exposed to acute kidney injury showed that renal protection promoted by ENT
inhibitors involves the A2B adenosine receptor. In addition, Eltzschig and colleagues demon‐
strated that the A2B receptor serves anti-inflammatory and tissue-protective roles in various
acute injury tissue models associated with hypoxic or ischemic injury including the heart [217],
lung [227], intestine [218] and kidney [226] using genetic (A2B receptor knockout mice) and
pharmacological (A2B receptor agonists) approaches. In summary, adenosine receptor signal‐
ing in hypoxic or ischemia-reperfusion injury varies depending on the receptor activation and
cell/tissue type. In general, A1 and A2A receptor activation has been shown to be protective in
the lung, kidney, heart and liver, whereas the role of the A2B and A3 receptors remains obscure.
A considerable number of studies both in vitro and in vivo have demonstrated the potential
of inosine in preventing injury in different models of hypoxia or ischemia.
In the early 1980s, it was demonstrated that infusion of 4 mM of inosine presented a protective
effect in fetal mouse heart organ cultures deprived of oxygen, a model of ischemic-like injury
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[228]. At the CNS level, purine catabolite concentrations were monitored for up to 15 h in the
auditory and somatosensory cortices of cats using microdialysis/HPLC and hydrogen
clearance following middle cerebral artery occlusion (MCAo). MCAo led to the release of
inosine and its metabolite hypoxanthine from the ischemic cortex in stroke animals, which
reached maximum levels 1-2 h after the onset of ischemia [229]. Cerebral infarct (stroke) often
causes devastating and irreversible losses of function, in part because of the brain’s limited
capacity for anatomical reorganization. In an animal cerebral ischemia model, which results
from infarction in the right dorsolateral cerebral cortex and underlying striatum, continuous
infusion of inosine 50 mM into the cisterna magna using osmotic minipumps (0.25 μl/h)
stimulated neurons on the undamaged side of the brain to extend new projections to dener‐
vated areas of the midbrain and spinal cord and consequently improved performance on
several behavioral measures in adult rats [230].
Taken together, these data suggest that inosine promotes neuroregeneration after stroke. An
interesting study recently published Shen and colleagues demonstrated that intracerebroven‐
tricular administration of inosine (25 nmol/L in 25 μL) before middle cerebral artery occlusion
in rats resulted in a higher level of locomotor activity (lasting up to 2 weeks after stroke) and
less cerebral infarction [231]. In addition, they indicated that coadministration of a selective
A3 receptor antagonist, MRS1191, significantly attenuated inosine-mediated protection.
Moreover, in the electrophysiological study, inosine antagonized glutamate-induced excita‐
tion in cerebral cortical neurons. In summary, the authors proposed that inosine may inhibit
glutamate postsynaptic responses and reduce cerebral infarction via the activation of the A3
receptor, presenting a neuroprotective action (Figure 3) [231].
6.5. Inflammatory bowel disease
Inflammatory bowel disease (IBD) is a common and lifelong disabling gastrointestinal disease
that includes Crohn’s disease (CD) and ulcerative colitis (UC) [232]. Worldwide UC incidence
varies greatly, ranging from 0.5-24.5 /100,000 habitants, and CD ranges from 0.1-16/100.000
habitants, with the highest incidence in developed countries [233]. Genetic, environmental,
and immunological factors interplay in a complex manner to contribute to the genesis of IBD.
Generally, the presence of one or more genetic factors triggers an over-reaction of the host
mucosal immune system to normal constituents of the mucosal microflora. This over-reaction
involves either a Th1-type T cell-mediated inflammation in the case of Crohn’s disease or a
Th2-type T cell-mediated inflammation in ulcerative colitis. This inflammatory process leads
to the release of multiple cytokines, including interferon (INF)-γ, tumor necrosis factor (TNF)-
α, interleukin (IL)-1,, IL-6, IL-8, IL-12, IL-13,IL-17, and monocyte chemotactic protein (MCP)-1
[234]. These cytokines are responsible for the attraction and activation of neutrophils, eosino‐
phils, mast cells and macrophages, which, in turn, produce large amounts of unstable chemical
species such as reactive oxygen species (ROS) or oxyradicals (i.e., superoxide anions, hydrogen
peroxide, hydroxyl radicals, and peroxynitrite), mediators that contribute greatly to the tissue
injury seen in IBDs [235, 236].
In early stages of immune or inflammatory response, significantly elevated extracellular
concentrations of adenosine are anti-inflammatory and tissue protective. Thus, one of the most
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widely used strategies to study the effects of adenosine on different inflammatory processes
involves inhibition of adenosine catabolism, mainly through inhibition of adenosine deami‐
nase (increasing adenosine levels) or direct activation of adenosine receptors. Antonioli and
colleagues have demonstrated, using a model of 2,4-dinitrobenzenesulfonic acid (DNBS)-
induced colitis, that treatment with 4-amino-2-(2-hydroxy-1-decyl) pyrazole[3,4-d]pyrimidine
(APP; novel adenosine deaminase inhibitor) or erythro-9-(2-hydroxy-3-nonyl)adenine
hydrochloride (EHNA; standard adenosine deaminase inhibitor) for up to 7 days was able to
increase food intake and weight gain and ameliorate macroscopic and microscopic inflamma‐
tory colonic alterations with a concomitant reduction of mucosal and plasmatic pro-inflam‐
matory mediators such as TNF-α and interleukin-6 [237]. In the same vein, Siegmund and
colleagues showed that treatment with {4-amino-1-(5-amino-5-deoxy-1-β-d-ribofuranosyl)-3-
bromo-pyrazol[3,4-d] pyrimidine} (GP515), an inhibitor of adenosine kinase, the enzyme
responsible for the conversion of adenosine to AMP, resulted in a significant improvement of
mucosal morphology and clinical score (weight loss, stool consistency, and bleeding) as well
as decreased IFN-γ concentration in the colonic tissue in dextran sulfate sodium (DSS)-induced
colitis [238]. These results clearly demonstrate that increased levels of adenosine can attenuate
mucosal inflammation in experimental colitis. The activation of adenosine A2A receptors seems
to be one of the main mechanisms involved in the effects of adenosine (Figure 3).
Odashima and colleagues studied the anti-inflammatory effects of ATL-146e in acute and
chronic rabbit formalin-immune complex models of colitis and the SAMP1/YitFc mouse model
of spontaneous ileitis. ATL-146e (20 and 40 μg/kg, i.p.) significantly reduced the acute and
chronic inflammatory index and tissue necrosis and prevented mortality. Furthermore, TNF-
α, IFN-γ and IL-4 concentrations were significantly suppressed with ATL-146e treatment in
supernatants from cultures of mesenteric lymph node cells of SAMP1/YitFc mice. Thus, these
results support important anti-inflammatory actions of ATL-146e in the intestine, including
the suppression of lymphocyte-derived cytokine-mediated pro-inflammatory responses,
suggesting that the activation of A2A receptor-mediated signaling through selective agonists
may be a novel therapeutic approach for patients with IBD [77]. To this end, Cavalcante and
colleagues evaluated the effects of a new selective A2A receptor agonist (ATL 313) on Clostridium
difficile toxin A-induced injury in murine ileal loops. ATL 313 treatment directly into ileal loops
significantly reduced toxin A-induced secretion and edema, prevented mucosal disruption,
neutrophil infiltration, TNF-α production, adenosine deaminase activity and prevented toxin
A-induced cell death. Based on these findings, the adenosine system may represent a prom‐
ising target for therapies for inflammatory intestinal disorders, either by manipulating its
metabolism or through direct activation of its receptors, especially A2A receptors [239].
6.6. Multiple sclerosis
MS is an autoimmune disease mediated by T cells that is characterized by CNS demyelination
and neurodegeneration [98]. There are many other diseases that are associated with inflam‐
mation of the CNS, including meningitis, encephalitis, among others. However, one of the
most common is MS. It affects more than 2.5 million people around the world and is charac‐
terized by the loss of neurological function, which occurs due to axonal demyelination and
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represents the main symptom of the disease. Recurrences, commonly associated with in‐
creased lymphocyte infiltration of the CNS, make the patient increasingly weak over time
[240-242].
Studies in mice using an EAE model demonstrated that adenosine signaling modulates the
development of EAE. A2B receptor blockade with CVT-6883 and MRS-1754 (both specific
antagonists of A2B) promoted a reduction in the symptoms of EAE, thus protecting against
CNS immune response damage. Moreover, both deletion and A2B receptor blockade promoted
inhibition of the differentiation of Th17 cells due to the reduction of IL-6 production by APCs
(dendritic cells), suggesting that the A2B receptor is a potential new target for "anti-multiple
sclerosis" drug action [98]. Post-mortem analysis of brain tissue from patients diagnosed with
MS showed the presence of cells with high expression of inducible nitric oxide synthase (iNOS)
and nitrotyrosine in characteristic lesions of the disease [243, 244].
Figure 3. Adenosine deleterious and protective effects in inflammation and immunity. A1, adenosine A1 receptor; A2A,
adenosine A2A receptor; A2B, adenosine A2B receptor; A3, adenosine A3 receptor; ATP, adenosine triphosphate; AMP,
adenosine monophosphate; ADO, adenosine; CD 39, ectonucleoside triphosphate diphosphohydrolase.
Peroxynitrite, the end product of iNOS activity, which leads to the formation of NO and then
to superoxide reaction, is highly reactive, causing a variety of toxic chemical changes in nerve
tissue, including the nitration of tyrosine residues [245]. It has been previously described that
UA, which is the final product of purine metabolism in humans, is a peroxynitrite scavenger
[246], and for this reason UA therapy has become a potential method to alleviate the neuronal
damage induced by peroxynitrite in MS treatment. Furthermore, inosine, an endogenous
precursor of UA, seems to be an attractive candidate for the treatment of MS, given that patients
who received inosine showed some evidence of clinical improvement and no sign of disease
progression [247]. In addition, recent studies using adenosine receptor antagonists as well as
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mice that were not capable of hydrolyzing adenosine from extracellular AMP (CD73-/), have
suggested that blockade of adenosine receptors or CD73 deletion protected mice from EAE,
decreasing lymphocyte infiltration in the CNS [248]. One very interesting note about the
involvement of the adenosinergic system during EAE is that both CD73 and A2A receptor
presented increased expression in the choroid plexus [248, 249] in comparison to other regions
of the CNS. This result shows that choroid plexus is higher permeable to lymphocytes than
other regions, therefore, it is speculated that ATP, released as result of damage, and its
conversion to adenosine represent a signal that regulates the entry of lymphocytes into the
CNS [250, 251].
7. Adenosine receptors as drug targets: future directions for new drug
development
There is increasing interest in the therapeutic potential of adenosinergic compounds (including
receptor agonists and antagonists, enzyme inhibitors and others), and many adenosine
compounds have been evaluated for therapeutic use. For a long time, adenosine itself was the
only adenosine agonist used in humans. It is widely used in the treatment of paroxysmal
supraventricular tachycardia (Adenocard®) due to the activation of A1 receptor and is also
used as a diagnostic tool for myocardial perfusion imaging (Adenoscan®) as a consequence
of its A2A receptor-activating effects, resulting in vasodilation [87].
Spinal administration of adenosine and adenosine analogs in humans also exhibited an
analgesic effect. A phase I clinical safety study in healthy volunteers demonstrated that 1000
μg of adenosine given intrathecally led to a significant decrease in mustard oil-induced
inflammatory pain and tourniquet-induced ischemic pain and decreased areas of secondary
allodynia after skin inflammation with low side effects [252]. Recently, some studies have
demonstrated new approaches regarding the development of allosteric modulators that
enhance the potency of endogenous agonists and aim to minimize the side effects [253].
Allosteric enhancers of the adenosine A1 receptor have been linked to anti-arrhythmic and
anti-lipolytic activity and also have therapeutic potential as analgesics. Oral administration of
the A1 receptor-selective allosteric enhancer T-62 was shown to reduce hypersensitivity in
carrageenan-inflamed rats and was approved for phase I clinical trials for neuropathic pain
treatment [254]. As was previously discussed, various studies of selective agonists and
antagonists demonstrated pro-inflammatory effects of A1 receptors in different inflammatory
models [47]. One interesting study showed a decrease in leukocyte infiltration and reduced
lung edema in rats treated with the A1 receptor antagonist L-97-1 [255]. Furthermore, the
selective A2A receptor agonists, apadenoson, binodenoson and sonedenoson have been
considered candidates for clinical use in cardiovascular disorders [189, 256, 257]. These
agonists are of interest as vasodilator agents in cardiac imaging [258] and as inflammation
suppressors. Moreover, as reported by Press and Fozard (2010), two clinical trial applications
from Santen Pharmaceuticals claim that use of agonist of adenosine receptors such as regade‐
noson and sonedenoson [259] is useful in the treatment of glaucoma.
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The A2A receptor agonist BVT.115959 from Biovitrum completed clinical trials for diabetic
neuropathic pain, and it was well tolerated but did not significantly improve pain symptoms
[260].The primary indication claimed for A2A receptor antagonists is in Parkinson’s disease
[261] because animal studies indicated that adenosine A2A receptors are localized with
dopamine D2 receptors in the striatum and provide an antagonistic interaction between
adenosine and dopamine [262]. Vernalis plc and Biogen Idec are currently profiling BIIB014
(V2006) in Phase II clinical trials for Parkinson’s disease [263]. Patents for A2B receptor
antagonists generally claim asthma and allergic diseases as the primary indications, in line
with current views on the receptor’s role in vivo [163]. CVT-6883, an A2B-adenosine receptor
antagonist, is in clinical development for the treatment of asthma, and this antagonist signif‐
icantly inhibits in vivo growth of B-16 tumors compared to taxol, as described in a recent review
[259].
A3 receptor selective agonists are also currently in clinical trials and exhibit nanomolar affinity
to the receptor. In this context, CF101 (Can-Fite Biopharma) and Cl-IB-MECA (CF102) are in
trials for autoimmune inflammatory disorders and liver cancer, respectively. Two other A3
receptor selective agonists, CP-608,039 and its N6-(2,5-dichlorobenzyl) analog, CP-532,903,
were previously under development for cardioprotection [264, 265]. Allosteric modulators of
the A3 receptor have also been developed, such as imidazoquinolines (LUF6000), which have
been shown to inhibit adjuvant-induced paw joint swelling in an arthritis rat model [265].
8. Conclusion
This chapter presented a general and updated review of the therapeutic potential of adenosi‐
nergic system (including receptor agonists and antagonists, enzyme inhibitors and others) in
the control of inflammatory and immune responses. Recently, is becoming clear that both
adenosine and inosine play primordial roles in regulating the inflammatory process, working
together for example as danger signals, in order to constitute a homeostatic mechanism of
tissue integrity. Furthermore, adenosine as well inosine effects are mediated by adenosine
receptors and depending on the tissue or cells where they are expressed, pro-inflammatory or
anti-inflammatory effects are observed. In this regard, several preclinical studies are conducted
to clarify the role of these purines during the inflammatory response and to better understand
the adenosine receptors activation which has becoming interesting target to control inflam‐
mation. Currently, adenosine is used in the clinical setting, especially in emergency units, to
convert sinus rhythm of paroxysmal supraventricular tachycardia (PSVT) to normal sinus
rhythm, with excellent cost/effectiveness. Besides the differences in receptor expression
between rodents and humans, the use of experimental animal models that can mimic the main
features of inflammatory and immune diseases, the improvement of biochemical, genetic and
molecular techniques have help us to better establish a translation between preclinical and
clinical effects of adenosine and inosine, and to develop and test selective agonists and
antagonist of adenosine receptors that can be used in the future treatment of chronic diseases
with inflammatory and immune features.
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